Core Viewpoint - The implementation of the National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug Catalog (2025) marks a significant milestone in improving access to innovative treatments for patients, particularly for thyroid eye disease (TED) patients in China [1] Group 1: Drug Introduction and Impact - The first prescription of the targeted drug Tislelizumab (信必敏) was issued on the same day the new drug catalog was implemented, highlighting its immediate availability to patients [1] - Tislelizumab is the first and only targeted therapy in China that can reverse proptosis, with a response rate of 85.8% and an overall eye efficacy rate of 94.2% [1] - The drug's price has decreased by approximately 60% after being included in the insurance coverage, significantly reducing the financial burden on patients [1] Group 2: Patient Demographics and Disease Prevalence - There are over 4 million patients suffering from thyroid eye disease in China, indicating a substantial market for effective treatments [1] - The condition often leads to serious symptoms such as proptosis and vision impairment, underscoring the need for effective therapeutic options [1]
信达生物替妥尤单抗纳入医保首日 甲状腺眼病患者受益